CODX

Co-Diagnostics Inc

Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast PR Newswire SALT LAKE CITY, April 30, 2026...

Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C. Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C. PR Newswire SALT LAKE CITY...

Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich...

Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah...

Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City PR Newswire SALT LAKE CITY, April...

The molecular diagnostics sector continues to evolve as companies shift focus from pandemic-driven demand toward broader infectious disease testing, global distribution networks, and next-generation platforms powered by artificial intelligence. As regulatory pathways reopen and international markets expand, companies with scalable, adaptable technologies are working to reposition themselves for long-term growth.Shares of Co-Diagnostics, Inc. (NASDAQ: CODX) finished Tuesday higher after the company reported its full-year 2025 financial results and outlined progress across its global ...

The molecular diagnostics sector continues to evolve as companies shift focus from pandemic-driven demand toward broader infectious disease testing, global distribution networks, and next-generation platforms powered by artificial intelligence. As regulatory pathways reopen and international markets expand, companies with scalable, adaptable technologies are working to reposition themselves for long-term growth.Shares of Co-Diagnostics, Inc. (NASDAQ: CODX) finished Tuesday higher after the company reported its full-year 2025 financial results and outlined progress across its global ...

Co-Diagnostics Reports Full Year 2025 Financial Results Co-Diagnostics Reports Full Year 2025 Financial Results PR Newswire SALT LAKE CITY, March 31, 2026 Advancing Global Commercialization Strategy...

Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization Co-Diagnostics Ships...